These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 403001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Induction of resistance to ascites tumor in mice with MFS-180 cells treated with glutaraldehyde, lipopolysaccharide, and concanavalin A.
    Nerkar DP, Chander R, Bandekar JR, Lewis NF.
    Cancer Res; 1981 Jul; 41(7):2922-4. PubMed ID: 6788363
    [Abstract] [Full Text] [Related]

  • 4. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM, Kawashima K, Nakashima I, Nagase F.
    Cancer Res; 1988 Nov 15; 48(22):6450-4. PubMed ID: 3263189
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification and characterization of a unique tumor-associated surface antigen on L1210 leukemia cells recognized by semisyngeneic antisera.
    Yokochi T, Kawashima K, Nakashima I, Nagase F, Isobe K, Nagura E, Yamada K, Miyadai T, Kimura Y.
    Cancer Res; 1987 Feb 15; 47(4):1006-9. PubMed ID: 3542198
    [Abstract] [Full Text] [Related]

  • 7. Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia.
    Relyveld EH, Bizzini B, Ophir R, Ben-Efraim S.
    Cancer Treat Rep; 1987 Mar 15; 71(3):241-6. PubMed ID: 3102055
    [Abstract] [Full Text] [Related]

  • 8. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
    Skórski T, Kawalec M.
    Exp Hematol; 1988 Oct 15; 16(9):782-4. PubMed ID: 3049130
    [Abstract] [Full Text] [Related]

  • 9. Blastogenic potency of concanavalin-A-bound L1210 leukemic vaccine associated with its immunogenic activity.
    Kataoka T, Oh-hashi F, Sakurai Y.
    Gan; 1979 Apr 15; 70(2):155-64. PubMed ID: 111995
    [Abstract] [Full Text] [Related]

  • 10. Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice.
    Skorski T, Kawalec M, Kawiak J.
    Bone Marrow Transplant; 1990 Jan 15; 5(1):23-7. PubMed ID: 2297588
    [Abstract] [Full Text] [Related]

  • 11. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC, Prager MD.
    Cancer Res; 1977 Feb 15; 37(2):507-13. PubMed ID: 832275
    [Abstract] [Full Text] [Related]

  • 12. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H.
    Transplant Proc; 1980 Sep 15; 12(3):388-90. PubMed ID: 6784299
    [Abstract] [Full Text] [Related]

  • 13. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
    Skórski T, Kawalec M.
    Bone Marrow Transplant; 1987 Dec 15; 2(4):435-40. PubMed ID: 3332191
    [Abstract] [Full Text] [Related]

  • 14. T cell-mediated cytotoxicity against trinitrophenyl-modified cells: effect of glutaraldehyde treatment on the immunogenicity and antigenicity of trinitrophenyl-modified cells.
    Forman J.
    J Immunol; 1977 May 15; 118(5):1755-62. PubMed ID: 404357
    [Abstract] [Full Text] [Related]

  • 15. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes.
    Fuji H, Murakami M.
    J Natl Cancer Inst; 1983 Jan 15; 70(1):119-25. PubMed ID: 6296515
    [Abstract] [Full Text] [Related]

  • 16. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.
    Kawashima K, Takeyama H, Takahashi T, Kato Y, Watanabe E, Suzuki H, Minam S, Isobe K, Yamada K, Ito Y.
    Gan; 1979 Dec 15; 70(6):769-76. PubMed ID: 94022
    [Abstract] [Full Text] [Related]

  • 17. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A, Canti G, Goldin A.
    Cancer Res; 1974 Nov 15; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract] [Full Text] [Related]

  • 18. Induction of tumor resistance in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus).
    Takeyama H, Kawashima K, Yamada K, Ito Y.
    Gan; 1979 Aug 15; 70(4):493-501. PubMed ID: 229053
    [Abstract] [Full Text] [Related]

  • 19. Tumor immunoprophylaxis in mice using glutaraldehyde-treated syngeneic tumor cells.
    Frost P, Sanderson CJ.
    Cancer Res; 1975 Oct 15; 35(10):2646-50. PubMed ID: 50879
    [Abstract] [Full Text] [Related]

  • 20. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L, Fuji H.
    Cancer Res; 1983 Jun 15; 43(6):2592-9. PubMed ID: 6342755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.